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This study was designed to test the hypothesis that vasodilator drugs can enhance selective 
heating of solid tumors by producing a favorable redistribution of blood flow between tumor and 
normal tissues. Subcutaneous transmissible venereal tumor implants were heated by inductive 
diathermy using Helmholtz coils in 8 dogs. The temperature rise in tumor and adjacent muscle 
was measured before and after giving hydralazine (0.5 mg/kg i.v.). Blood flow to the tumors and 
underlying muscle was measured with radioactive tracer microspheres. Before hydralazine 
treatment mean muscle blood flow was about one-third tumor blood flow (0.11  0.02 vs. 0.28  
0.09 ml/min/g), and tumor and normal muscle temperatures were not significantly different (40.0 
 0.6 vs. 39.7  0.l oC). After hydralazine tumor blood flow decreased and muscle blood flow 
increased in every dog, and selective heating of the tumors became possible. Muscle blood flow 
averaged 0.67  0.13 ml/min/g, 17 times greater than tumor blood flow, which decreased to 0.04 
0.02 ml/min/g. Core tumor temperature was 48.0  0.9 vs. 38.5  0.5 oC for underlying muscle. 
Blood pressure was maintained at 80  5.7 mmHg. These results demonstrate that adjuvant 
treatment with vasodilators is a promising technique to increase the temperature difference 
between tumors and surrounding normal tissues during local heat therapy.  
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Local hyperthermia therapy for cancer involves the application of microwaves, radiofrequency 
current, or high intensity ultrasound to warm only the tumor-bearing region while core body 
temperature is maintained near 37°C. Such local heat treatment is now being tested clinically at 
several institutions with encouraging, but not uniformly successful, results [1-7]. The goal of 
local heat therapy is to raise the temperature of the tumor mass to a lethal leve1 [8-10] without 
damaging surrounding normal tissue. Ideally, the temperature of the entire tumor would be raised 
to cytotoxic levels, which drop abruptly at the tumor edge to levels not damaging to normal 
tissues. 
 
In practice, the tissue temperatures actually attained depend on the balance between the rate of 
heat deposition and the rate of heat removal from the tissues [l0, 11]. The results of animal 
experiments [12] and computer modeling [10, 11] clearly show that blood perfusion is the 
primary mechanism for heat removal from tissue volumes greater than a few cubic centimeters. 
Hence, many authorities now believe that the relatively low blood flow found in certain tumors 
as compared to surrounding normal tissue explains the selective heating of tumor tissue often 
observed during local hyperthermia [1-3, 10, 13-15]. Presumably, such blood flow differences 
are the result of functional differences between tumor and normal microvasculature. 
 
Tumor vessels are typically enlarged, elongated capillaries without smooth muscle, which 
remain maximally dilated at all times [16-18]. As a result, tumor vasculature presents a fixed 
resistance to blood flow. In contrast, normal arterioles in adjacent tissues maintain a high degree 
of autoregulatory control over local blood flow and are capable of responding to heat and 
metabolic alterations, as wel1 as to vasoactive drugs. We hypothesized, therefore, that this 
difference in the responsiveness of tumor and normal vasculature can be manipulated to produce 
selective temperature elevation in a tumor during local heat therapy [19, 20]. Specifically, 
pretreatment of a patient with a direct-acting vasodilator drug would be expected to lower 
vascular resistance in normal tissues, increasing perfusion in them, while simultaneously 
shunting blood flow away from the tumor. Such effects have, in fact, been described in 
experimental animals for the vasodilators isoproterenol, chlorpromazine, amyl nitrate [21] and 
prostaglandin E2 [22]; and in human patients for the vasodilator prostaglandin El [23]. 
 
Accordingly, we performed the following study to determine the effect of the direct acting 
vasodilator, hydralazine, on the distribution of blood flow and the temperature rise in tumor and 
adjacent normal tissue during local heat therapy. We studied the canine transmissible venereal 
tumor because its size and geometry approximate those of human tumors. 
 
 
MATERIALS AND METHODS  
 
Transplantation of the canine transmissible venereal tumor (TVT) 
 
Serial transplantation was performed by subcutaneous injection of single-cel1 suspension 
prepared by trypsinization of primary tumors according to the methods of Epstein and Bennett 
[24] and Cohen [25]. Each dog received an inoculation (2-4 x 10
8
 cells) in the media1 aspect of 
3 
 
the upper hindlimb. At the time of the experiment, tumor weight ranged from 22 to 100 grams 
(mean, 55 g) after a growing period of 41-110 days (mean, 56 days).  
 
Animal preparation and thermometry 
 
Eight tumor-bearing mongrel dogs weighing 7.0-19.5 kg were used. Anesthesia was induced 
with thiopental sodium and maintained by methoxyfluorane, nitrous oxide, and oxygen 
inhalation. Dogs were placed in dorsal recumbency on a V-shaped animal board. Catheters were 
placed in the left ventricle for injection of radioactive tracer microspheres to measure blood flow; 
in the right brachial artery for withdrawal of reference blood samples; in the left brachial artery 
for monitoring blood pressure; and in a brachial vein for drug and fluid administration. 
 
Hollow, open-ended plastic cannulae (1 mm diameter) were inserted into the tumor center and 
into normal muscle underlying the tumor. These cannulae permitted repeated insertion and 
withdrawal of rapidly responding (0.1 sec rise time) hypodermic-style thermistors (Yellow 
Springs Instruments Co., Inc., Yellow Springs, OH, U.S.A.) for monitoring tissue temperature. 
These temperatures were recorded on a 2-channel rectilinear strip-chart recorder (Houston 
Instruments, Houston, TX, U.S.A.). A flexible temperature probe was placed in the esophagus, at 
the leve1 of the heart, to monitor core body temperature. Arterial blood pressure and core body 
temperature were recorded continuously by a graphic recorder.  
 
Microsphere technique  
 
The use of radioactively labeled tracer microspheres to measure regional blood flow is well-
established [22, 26, 27]. In this study tracer microspheres (3M Co., Minneapolis, MN, U.S.A.) 









Sc]) were employed, allowing four blood flow measurements 
to be made during the experiment. The microspheres were suspended in 10% dextran. For each 
trial a 2.0 ml aliquot of well-mixed suspension containing approximately 10
6
 microspheres was 
injected into the left ventricle and the catheter was flushed with 10 m1 of 0.9% saline. This 
catheter had multiple side-holes to promote homogeneous mixing of the microsphere suspension 
with blood.  
 
A reference blood sample was collected from the right brachial artery into a motor-driven 
syringe at a constant rate of 7.3 ml/min, starting 10 sec before the injection of microspheres and 
continuing for a total of 120 sec. This sample provided a known blood flow into a ‘reference 
organ’ for the purpose of calibrating regional blood flow in tissue samples. To determine tissue 
perfusion at the end of each experiment, the heated tumor was excised, weighed, and placed in 
plastic vials for determining radioactivity. Several samples of underlying muscle tissue were also 
taken. Measurement of the radioactivity, in counts per minute (counts/min), due to each of the 
four radionuclides in each tissue sample, and in the four reference blood samples, was performed 
by a Beckman 8000 -spectrophotometer. The blood flow in each tissue sample was calculated 






The blood flow values determined for each sample were divided by the weight of that sample to 
provide a value for tissue perfusion expressed in ml/min/g. Total flow (cardiac output) was also 




Experimental design  
 
We selected the vasodilator, hydralazine, for this study because (1) it is direct-acting, having 
selective action on arterioles; (2) it has a relatively long duration of action; and (3) it is clinically 
safe and widely used in human medicine [28, 29]. To study the effect of hydralazine on the 
distribution of blood flow between normal and tumor tissue and to relate the flow distribution to 
heating, blood flow and temperature of tumor and underlying normal tissue were measured under 
four different conditions. First, [
141
Ce]-labeled microspheres were injected (Trial 1) to measure 
the control leve1 of blood flow after blood pressure, core temperature, and tissue temperature 
had stabilized following surgery (about 30 min). The tumor-bearing region of one hindlimb was 
then heated by passing 13.56 MHz radiofrequency current, generated by a Birtcher diathermy 
unit (Birtcher Corporation; El Monte, California, USA), through a set of Helmholtz coils which 
encompassed the region. 
 
The arrangement of the coils and tumor-bearing limb is depicted in Fig. 1. The coils were 
positioned such that the sites of temperature measurement in tumor and normal tissue were 
exposed to approximately the same field strength. To avoid interactions between the thermistors 
and the induced magnetic field, we employed a pulsed heating technique. Several heating 
episodes lasting 1-5 min each were used to bring the temperature of the normal tissue to a 
steady-state target level of approximately 40°C. Tissue temperatures were only monitored during 
the short period (approximately 1 min) between heating episodes when the radiofrequency 
current was turned off. The thermistors were removed from the cannulae during radiofrequency 
heating to prevent current concentration near the tip of such a conductive implant, which may 
have caused tissue damage as wel1 as self-heating of, and possible damage to, the thermistors 
[30]. [
85
Sr]-labeled microspheres were injected (Trial 2) when the target temperature had been 







Fig. 1. Schematic diagram depicting the orientation of the Helmholtz coils with respect 
to the tumor-bearing limb. Sites 1 and 2 indicate the positions of cannulae in the tumor 
and underlying muscle for insertion of hypodermic-style thermistors. 
 
 
As the temperatures of the tumor and surrounding normal tissue returned to baseline values, 
hydralazine was injected intravenously (0.5 mg per kg body weight). Arterial blood pressure was 
monitored to determine the onset of drug effect (tachycardia and increased pulse pressure). When 
the effect of the drug on pulsatile blood pressure had stabilized (approximately 15 min), [
95
Nb]-
labeled microspheres were injected (Trial 3) to determine the change in distribution of perfusion 
due to hydralazine alone.  
 
Finally, the tumor-bearing region was heated as before in the presence of hydralazine effect. The 
position of the Helmholtz coils and the sites of temperature measurement remained unchanged. 
A steady-state temperature of approximately 40°C for the normal tissue again served as a target. 
After the target temperature had been maintained for at least 10 min, [
46
Sc]-labeled microspheres 
were injected (Trial 4).  
 
At the end of the experiment, dogs were killed by an injection of saturated KCl solution 
(approximately 2 ml) into the left ventricle and tissue samples were excised for weighing and 
determination of radioactivity. The Mann-Whitney statistics were calculated for the blood flow 
and temperature data for each trial to test the nul1 hypotheses that the blood flow rates and 







Redistribution of blood flow 
 
Figure 2 presents the mean blood flow data for tumor and underlying muscle samples obtained 
under the four test conditions previously described. Under normothermic control conditions 
(Trial 1) the TVT had a significantly greater leve1 of perfusion than the adjacent muscle (u = 8.0; 
P  0.01). After heating alone (Trial 2), tumor and muscle blood flows were not significantly 
different. The addition of hydralazine under normothermic conditions (Trial 3) greatly increased 
tissue perfusion in the muscle samples to a leve1 5.4 times the control value. At the same time 
perfusion of the tumor tissue dropped to about one-half of the control value. These changes were 
slightly enhanced by heating. The final observations, after heating (Trial 4), revealed that 
perfusion of the normal tissue, rather than being about one-third that of the tumor tissue 




Fig. 2. Mean blood flow data for tumor and underlying normal muscle obtained during 
four different test conditions: normothermic, no drug (Trial 1); hyperthermic, no drug 
(Trial 2); normothermic, hydralazine (Trial 3); and hyperthermic, hydralazine  








Fig. 3. (A) Intratumor and underlying normal muscle temperatures attained without 
hydralazine (Trial 2). (B) Intratumor and underlying normal muscle temperatures 





The complete temperature-time curves for a typical experiment are shown in Fig. 3. 
Temperatures attained after local heating for tumor and underlying muscle in al1 8 experiments 
are presented in Table 1. When the temperature of the normal tissue was raised to a steady-state 
target leve1 of approximately 40 °C before giving hydralazine, the temperature measured in the 
tumor was never higher than 42.5 
o
C and never more than 2.5 
o
C higher than normal tissue 
temperature. In 4 of the 8 dogs it was impossible to raise the temperature of the tumor to a leve1 
higher than the normal tissue before hydralazine treatment. When, after the injection of 
hydralazine, the temperature of the normal tissue was again raised to a target leve1 of about 40 
o
C, tumor temperature rose as high as 51.6 
o
C. Although the positions of the Helmholtz coils 





C) were obtained after hydralazine (Table 1). In every animal, hydralazine 





Table 1. Final temperatures (
o
C) attained after local heating 














Table 2 presents cardiac output, blood pressure and total peripheral resistance values obtained at 
the times of microsphere injection. At the doses of hydralazine employed, total peripheral 
resistance dropped to approximately one-half the control value, mean blood pressure was 
significantly less than control, but cardiac output increased by about 50%. Although mean 





Pretreatment of TVT-bearing dogs with the direct-acting vasodilator , hydralazine, produced a 
highly favorable redistribution of blood flow between normal and tumor tissue, making possible 
selective heating of the tumors to therapeutic temperatures. Although the present protocol is 
limited in that only one tumor model was studied, this particular model provided a rigorous test 
of the specific therapeutic effect of hydralazine. Prior to hydralazine treatment normal muscle 
blood flow was no greater--and usually much less--than tumor blood flow, making selective 
tumor heating impossible. After hydralazine treatment normal muscle blood flow averaged 17 
times that in the tumor and an average temperature difference of 9.5 
o
C was observed.  
 
Dickson and Calderwood’s [8] compendium of single-treatment thermal death times for various 




where T = tumor temperature ( 
o
C) and t = required exposure time for tumor necrosis (hr) [10]. 
According to this relationship, for the intratumor temperatures achieved in this study, irreversible 
damage could be expected in as little as 4.1 min (at 51.6 °C ) to 42 min (at 45 °C). At the same 
time, the increased perfusion of surrounding normal tissue produced by hydralazine kept normal 
tissue temperature wel1 below 42 °C.  
 
Selective tumor heating of the magnitude achieved in this study has rarely been described. 
However, when comparable heating is achieved clinically the results are encouraging. Storm 
reported that in more than three-quarters of the human tumors in which temperatures of 42-50 °C 
were achieved by radiofrequency heating, minima1 normal tissue injury was sustained, while 
moderate to marked necrosis occurred in successfully heated tumors [1]. LeVeen et al. showed 
that radiofrequency therapy producing a mean intratumor temperature of 48.4 °C in seven 
patients consistently caused necrosis of cancerous tissue with little destruction of normal tissue 
[3]. It is likely, therefore, that treatment with a vasodilator drug prior to local hyperthermia 
therapy will increase the number of tumors which can be selectively heated while decreasing the 




The therapeutic effect of hydralazine observed in this study was obtained at doses that did not 
depress blood pressure unacceptably. Although the drug decreased peripheral resistance by about 
one-half, blood pressure was maintained at reasonable levels by the reactive increase in cardiac 
output (Table 2). These effects are expected for a direct-acting vasodilator and appear to be 
within clinically reasonable limits.  
 
Ideally, cancer therapy should destroy neoplastic cells without injuring nearby normal cells, just 
as modern antibiotics destroy bacteria without damaging the host. Unfortunately, the chemical 
differences between cancer cells and normal cells are relatively subtle. However, we believe 
there are crucial anatomic and functional differences between tumor blood vessels and normal 
blood vessels, which make the whole tumor, as opposed to individual tumor cells, selectively 
vulnerable to local hyperthermia. The results of this study show that it is possible to treat a tumor 
as a specific ‘organ’ which responds to a drug in a qualitatively different manner than normal 
organs.  
 
For the TVT system, the difference in response to hydralazine was unequivocal: blood flow to 
normal tissue increased; blood flow to tumor tissue decreased. This functional difference is 
rationally related to well-reported anatomic differences between blood vessels in tumor and 
normal tissues; specifically, the lack of smooth muscle in the walls of tumor vessels [16, 17, 18]. 
This selective response was easily exploited to produce selective heating of the tumor. As local 
hyperthermia techniques improve, adjuvant treatment with vasodilators is likely to increase the 
intratumor temperatures that can be safely attained and decrease the severity of thermal damage 
to surrounding normal tissues. 
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